Glucagon-like peptide-1 (GLP-1)-based drugs have recently attracted significant attention as anti-obesity therapeutics [8]; however, their long-term use is associated with pancreatitis, thyroid cancer, and gastrointestinal complications [9,10]. Here, GCG is linked to obesity disorder.